GemPharmatech Co (SHSE:688046) Total Liabilities : ¥501.0 Mil (As of Jun. 2024)

View and export this data going back to 2022. Start your Free Trial

What is GemPharmatech Co Total Liabilities?

GemPharmatech Co's Total Liabilities for the quarter that ended in Jun. 2024 was ¥501.0 Mil.

GemPharmatech Co's quarterly Total Liabilities declined from Dec. 2023 (¥452.93 Mil) to Mar. 2024 (¥428.20 Mil) but then increased from Mar. 2024 (¥428.20 Mil) to Jun. 2024 (¥500.99 Mil).

GemPharmatech Co's annual Total Liabilities increased from Dec. 2021 (¥268.78 Mil) to Dec. 2022 (¥276.00 Mil) and increased from Dec. 2022 (¥276.00 Mil) to Dec. 2023 (¥452.93 Mil).

GemPharmatech Co Total Liabilities Historical Data

The historical data trend for GemPharmatech Co's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GemPharmatech Co Total Liabilities Chart

GemPharmatech Co Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

147.66

225.95

268.78

276.00

452.93

GemPharmatech Co Quarterly Data
	Dec18	Dec19	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
Total Liabilities	Get a 7-Day Free Trial													357.33	395.20	452.93	428.20	500.99

GemPharmatech Co Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

GemPharmatech Co's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	366.409	+	(36.071	+	50.453
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	452.9

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	2577.59	-	2124.656
	=	452.9

GemPharmatech Co's Total Liabilities for the quarter that ended in Jun. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	426.644	+	(37.382	+	36.961
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	501.0

Total Liabilities	=	Total Assets (Q: Jun. 2024 )	-	Total Equity (Q: Jun. 2024 )
	=	2614.187	-	2113.2
	=	501.0

GemPharmatech Co Total Liabilities Related Terms

Thank you for viewing the detailed overview of GemPharmatech Co's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

GemPharmatech Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GemPharmatech Co Ltd (SHSE:688046) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 12, Xuefu Road, Jiangbei New District, Jiangsu Province, Nanjing, CHN, 210032

Website

https://www.gempharmatech.us

GemPharmatech Co Ltd is a provider of?genetically engineered mouse?models?and services to global preclinical research and development communities. It specializes in developing animal models using cutting edge gene-editing technologies with a large collection of?cKO/KO (conditional knockout/knockout) mice, humanized mice, immunodeficient mice, and germ-free mice.

GemPharmatech Co Headlines

No Headlines